Belvedere Trading
TVRD

Belvedere Trading’s Tvardi Therapeutics TVRD Stock Holding History

Belvedere Trading’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-253
Closed -$198K – 460
2021
Q1 		$198K Buy
+253
New +$173K 0.02% 180

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Belvedere Trading's TVRD Position: Q2 2021 in Review

Belvedere Trading sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 61 shares — an estimated $48K sold.

Belvedere Trading first reported a position in TVRD in Q1 2021 and held it in 1 quarter. The position peaked at $48K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Belvedere Trading reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Belvedere Trading sold 61 Tvardi Therapeutics shares in Q2 2021, an estimated $48K.
  • Belvedere Trading first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 1 quarter.
  • Belvedere Trading's Tvardi Therapeutics position peaked at $48K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Belvedere Trading's 13F filing for Q2 2021, filed 23 Jul 2021.